The Scottish Medicines Consortium (SMC) has accepted Outlook Therapeutics’ Lytenava (bevacizumab gamma) for the treatment of ...

Roche's Genentech unit has won FDA approval for Susvimo, an implant for eyesight-robbing disease wet age-related macular degeneration (AMD) that gives patients an alternative to regular injections ...

The data from the phase 2 PRISM study comes from a cohort of 51 patients with wet or neovascular AMD, a form of the disease where abnormal blood vessels grow in the back of the eye. They all had ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.